Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicine composition for treating chronic liver disease

A technology for chronic liver disease and composition, which is applied in the field of medicines for the treatment of chronic liver disease, can solve the problems of difficult to understand the components contained, complex components, loss of characteristic advantages, etc.

Inactive Publication Date: 2009-02-11
SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
View PDF0 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no matter the traditional Chinese medicine compound or a single active ingredient has its shortcomings
Due to the complex composition of traditional Chinese medicine compound, it is difficult to understand the ingredients contained in it, which makes its preparations have certain controllability and stability problems. Distinctive Advantages of Conceptual Treatment of Complex Diseases

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine composition for treating chronic liver disease
  • Medicine composition for treating chronic liver disease
  • Medicine composition for treating chronic liver disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0019] The corresponding optimal composition for reducing liver collagen content is obtained by using the DMN-induced rat liver fibrosis model and the uniform design method for regression analysis.

[0020] Materials and methods:

[0021] Animals: Wistar male rats, clean grade, body weight (160±10) g, provided by Shanghai Experimental Animal Center, Chinese Academy of Sciences.

[0022] Main reagents and drugs: Dimethylnitrosamine (DMN), product of Tokyo Chemical Industry Co., Ltd.; Cordyceps sinensis polysaccharide: derived from Cordyceps, product of Shanghai Kangzhou Fungal Polysaccharide Co., Ltd., specification 95%, batch number : 20060828; Salvianolic acid B: extracted from the traditional Chinese medicine Salvia miltiorrhiza, from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, with a content greater than 60%; Amygdaloside: derived from almonds, Xi'an Guanyu Biotechnology Co., Ltd. The company's product, specification 98%, batch number: 06061; Gyp...

Embodiment 2

[0033] Using carbon tetrachloride-induced rat liver fibrosis model and uniform design method regression analysis to obtain the corresponding optimal formula for reducing liver collagen content.

[0034] Materials and methods:

[0035] Animals: 90 Wistar male rats, SPF grade, weighing 170±15g, were provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences.

[0036] Main reagents and drugs: carbon tetrachloride and olive oil were purchased from China Pharmaceutical Group. Cordyceps polysaccharide, salvianolic acid B salt, amygdalin, gypenosides are equivalent to "Example 1".

[0037] Uniform design drug screening experiment: 77 rats were randomly divided into normal group (7 rats) and model group (70 rats). Rats in the model group were injected subcutaneously with 100% CCl for the first time 4 Solution 3ml / kg, followed by 50% CCl 4Olive oil solution 2ml / kg, twice a week for 9 weeks. Rats in the normal group were injected with the same dose of ol...

Embodiment 3

[0048] Use the DMN-induced rat liver fibrosis model to verify the curative effect of the screened formulas A and B

[0049] Materials and methods:

[0050] Animals: SD male rats, clean grade, body weight (170±10) g, provided by Shanghai Experimental Animal Center, Chinese Academy of Sciences.

[0051] Main reagents and drugs: control drug Fuzheng Huayu Capsules (raw material, provided by Shanghai Modern Chinese Medicine Technology Development Co., Ltd.), liver function test kit (purchased from Nanjing Jiancheng Bioengineering Institute), other materials are the same as in "Example 1 ".

[0052] Grouping and modeling 60 SD rats were randomly divided into normal group (5) and modeling group (55). The modeling method was the same as in Example 1. After 4 weeks of modeling, 6 animals in the modeling group died. The remaining 49 model rats were randomly divided into model group (9 rats), A and B formula groups (8 rats each), A formula + salvianolic acid B group, B formula + salvi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention pertains to the field of traditional Chinese medicines and relates to a medicine for treating chronic liver diseases. The invention adopts the active ingredients or components in cordyceps polysaccharide, amygdalin and gypenosides with a specific mixture ratio to compose a drug composite with ideal therapeutic effects of resisting hepatic fibrosis and liver injury. By the model tests of classic animals and verification, results confirm that the medicine can remarkably reduce the collagen concentration of the liver tissues of rat models, lighten the degrees of hepatic fibrosis and liver injury and improve the effects of resisting hepatic fibrosis, effectively prevent the development of hepatic fibrosis and promote the reversion of hepatic fibrosis. The effects are better than that of individually using each ingredient; the medicine can be used for treating and preventing various diseases, such as chronic hepatitis, hepatic fibrosis, hepatocirrhosis and the like. The medicine can be prepared into oral solid preparations, such as granules, tablets, capsules and the like.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicines and relates to medicines for treating chronic liver diseases. In particular, it relates to an effective medicine with a traditional Chinese medicine component or a specific ratio of components that can improve the anti-hepatic fibrosis and anti-liver damage effects. Background technique [0002] Liver fibrosis is almost a common path for the development of various chronic liver diseases to cirrhosis, and its essence is the excessive deposition of extracellular matrix (ECM). Slowing down, preventing and reversing liver fibrosis is an important link in the treatment of liver diseases. But so far modern medicine still lacks good clinical treatment methods. [0003] The research progress of liver fibrosis abroad is mainly reflected in the in-depth study of the pathogenesis. Professor Friedman, a famous American liver fibrosis research expert, once analyzed: "The continuous elucidation o...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K36/424A61K36/736A61P1/16A61K31/715A61K31/7028
CPCA61K31/7036A61K31/704A61K36/068A61K31/715A61K45/06A61P1/16A61K2300/00
Inventor 胡义扬刘平李雪梅冯琴彭景华徐列明刘成海
Owner SHUGUANG HOSPITAL AFFILIATED WITH SHANGHAI UNIV OF T C M
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com